- Conditions
- Influenza
- Interventions
- Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 593
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
- Conditions
- HIV
- Interventions
- DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
- Interventions
- Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test
- Procedure
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 19 Years to 59 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Furosemide (plus potassium chloride), Placebo (plus placebo electrolyte solution)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Weeks to 10 Weeks
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
- Conditions
- Colorectal Cancer Screening
- Interventions
- Notification, Training
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 536 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Portland, Maine • Boston, Massachusetts • Danvers, Massachusetts + 1 more
- Conditions
- Pediatric Recurrent Central Nervous System Tumors
- Interventions
- Personalized neoantigen DNA vaccine, Papivax Biotech TDS-IM v2.0, Peripheral blood draw
- Biological · Device · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma, Lymph Node Cancer
- Interventions
- CMP-001, Nivolumab
- Drug · Biological
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recurrent Oligodendroglioma, Progressive Oligodendroglioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Seattle Project Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
- Conditions
- Glioblastoma, Adult
- Interventions
- Multiple dose of EO2401
- Biological
- Lead sponsor
- Enterome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
- Interventions
- ELA026
- Drug
- Lead sponsor
- Electra Therapeutics Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
- Conditions
- Haemophilus Influenzae Type b, Neisseria Meningitidis
- Interventions
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 15 Months
- Enrollment
- 4,441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- HIV Infections
- Interventions
- VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Grade IV
- Interventions
- Personalized peptide vaccine, Poly-ICLC, Temozolomide
- Biological · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
- Interventions
- Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
- Drug · Procedure
- Lead sponsor
- Shambavi Richard
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19
- Interventions
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- Human Papilloma Virus, Human Papilloma Virus Vaccine
- Interventions
- CDC 4 Pillars Program
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia
- Conditions
- Viral Diseases
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uncontrolled Hypertension, BMI, Stress, Medication Adherence
- Interventions
- Prime Time Sister Circle
- Behavioral
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 359 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Cancer
- Interventions
- health literacy appropriate education and demonstration, shared decision making, automated call reminders or automated texts
- Behavioral
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 804 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Bastrop, Louisiana • Marion, Louisiana • Saint Joseph, Louisiana
- Conditions
- Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Depression
- Interventions
- PRIME 1.0, PRIME 2.0
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California